GT200900123A - Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace - Google Patents

Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace

Info

Publication number
GT200900123A
GT200900123A GT200900123A GT200900123A GT200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A
Authority
GT
Guatemala
Prior art keywords
compounds
methods
inhibit
interaction
link molecule
Prior art date
Application number
GT200900123A
Other languages
English (en)
Inventor
Alfredo C Castro
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Thomas T Tibbitts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900123A publication Critical patent/GT200900123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EL PRESENTE INVENTO SE RELACIONA CON LOS COMPUESTOS HETEROCÍCLICOS QUE ENLAZAN LAS PROTEÍNAS BCL Y BLOQUEAN LA FUNCIÓN BCL. OTRO DE LOS ASPECTOS DEL PRESENTE INVENTO SE RELACIONA CON LAS COMPOSICIONES QUE COMPRENDEN UN COMPUESTO HETEROCÍCLICO DEL INVENTO. EL PRESENTE INVENTO PRESENTA MÉTODOS PARA TRATAR Y MODULAR LOS DESÓRDENES RELACIONADOS CON LA HIPERPROLIFERACIÓN, TAL COMO EL CÁNCER.
GT200900123A 2006-11-15 2009-05-12 Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace GT200900123A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Publications (1)

Publication Number Publication Date
GT200900123A true GT200900123A (es) 2011-09-02

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900123A GT200900123A (es) 2006-11-15 2009-05-12 Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace

Country Status (21)

Country Link
US (2) US7842815B2 (es)
EP (1) EP2094673B1 (es)
JP (2) JP2010510214A (es)
KR (1) KR101530721B1 (es)
CN (1) CN101583606B (es)
AU (1) AU2007319848B2 (es)
BR (1) BRPI0718606A2 (es)
CA (1) CA2669596C (es)
EC (1) ECSP099398A (es)
ES (1) ES2537762T3 (es)
GT (1) GT200900123A (es)
HK (1) HK1130057A1 (es)
IL (1) IL198597A (es)
MA (1) MA31067B1 (es)
MX (1) MX2009005184A (es)
MY (1) MY156754A (es)
NO (1) NO20092306L (es)
NZ (1) NZ577243A (es)
RU (1) RU2449996C2 (es)
TN (1) TN2009000182A1 (es)
WO (1) WO2008060569A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
BRPI0907754A2 (pt) * 2008-02-08 2015-07-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos terapêuticos
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8945853B2 (en) 2012-02-06 2015-02-03 Discoverx Corporation Detection of intracellular binding events by measuring protein abundance
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
WO2014078014A2 (en) 2012-11-14 2014-05-22 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
CA3103604C (en) 2016-03-28 2023-09-26 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
US20230270816A1 (en) 2020-07-06 2023-08-31 INSERM (Institute National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5494911A (en) 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
US5294617A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0623615B1 (de) * 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten
HUT74690A (en) 1993-11-24 1997-01-28 Du Pont Merck Pharma Novel isoxazoline and isoxazole fibrinogen receptor antagonists process for producing them and pharmaceutical compositions containing them
WO1995024398A1 (en) 1994-03-09 1995-09-14 Pfizer Inc. Isoxazoline compounds as inhibitors of tnf release
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
JP2000516234A (ja) 1996-08-16 2000-12-05 デュポン ファーマシューティカルズ カンパニー アミジノフェニル―ピロリジン類、アミジノフェニル―ピロリン類、およびアミジノフェニル―イソオキサゾリジン類およびそれらの誘導体
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
WO1998050030A1 (en) 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
DE60237115D1 (de) 2001-05-30 2010-09-02 Univ Georgetown Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
BRPI0511070A (pt) 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
WO2006009907A2 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法

Also Published As

Publication number Publication date
RU2009121808A (ru) 2010-12-20
AU2007319848A1 (en) 2008-05-22
AU2007319848B2 (en) 2012-05-03
CA2669596A1 (en) 2008-05-22
MA31067B1 (fr) 2010-01-04
IL198597A0 (en) 2010-02-17
US20080306127A9 (en) 2008-12-11
MX2009005184A (es) 2009-10-12
BRPI0718606A2 (pt) 2013-12-17
EP2094673B1 (en) 2015-04-08
CN101583606A (zh) 2009-11-18
NZ577243A (en) 2011-12-22
TN2009000182A1 (en) 2010-10-18
US8461191B2 (en) 2013-06-11
KR20090082284A (ko) 2009-07-29
ECSP099398A (es) 2009-07-31
JP2010510214A (ja) 2010-04-02
US7842815B2 (en) 2010-11-30
KR101530721B1 (ko) 2015-06-22
ES2537762T3 (es) 2015-06-11
WO2008060569A1 (en) 2008-05-22
NO20092306L (no) 2009-08-17
CA2669596C (en) 2014-09-30
US20110160259A1 (en) 2011-06-30
IL198597A (en) 2014-03-31
EP2094673A1 (en) 2009-09-02
US20070161690A1 (en) 2007-07-12
HK1130057A1 (en) 2009-12-18
JP2014055156A (ja) 2014-03-27
RU2449996C2 (ru) 2012-05-10
MY156754A (en) 2016-03-31
CN101583606B (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
GT200900123A (es) Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace
GT200600328A (es) Derivados de isoquinolona sustituidos con piperidinilo
ECSP088607A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con las parejas de unión
GT200600327A (es) Ciclohexilaminoisoquinolona
GT200900027A (es) Compuestos organicos
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
GT200900183A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
UY30840A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos
GT201000376A (es) Compuestos organicos
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
UY30843A1 (es) Derivados de isoquinolona sustituidos con ciloalquilamina
CL2007002424A1 (es) Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
PA8667201A1 (es) Nuevos compuestos farmaceuticos
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP10010705A (es) Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
GT200800102A (es) Compuestos y metodos para inhibir la interaccion de proteinas bcl con moleculas de enlace
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
CO6321288A2 (es) Sales de compuestos inhibidores de vih
HN2009000856A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.